Free Trial
→ Executive Order 14241 Unleashes Trump’s New Dollar (From Porter & Company) (Ad)tc pixel
NASDAQ:PAVM

PAVmed Q3 2026 Earnings Date & Estimates

PAVmed logo
$1.95 0.00 (0.00%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$1.93 -0.02 (-1.13%)
As of 06:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PAVmed is estimated to report Q3 2026 earnings on Friday, November 13, 2026, before market opens. The conference call is scheduled for 8:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from PAVmed in Q3 2026

PAVmed is expected to post earnings of -$0.63 per share on revenue of $25 thousand. PAVmed last reported on May 14, 2026, posting -$1.17 per share and missing the -$0.69 consensus estimate.

Consensus Estimates

Consensus EPS
-$0.63
Expected Revenue
$25 thousand

Recent Track Record

Last Reported
Q1 2026
Last Quarter EPS
-$1.17 (Missed by -$0.48)
Last Quarter Revenue
$22 thousand

Prepare for the Q3 2026 Call

PAVmed Q3 2026 Earnings FAQ

PAVmed (NASDAQ:PAVM) is estimated to report Q3 2026 earnings on Friday, November 13, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

PAVmed's Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect PAVmed to post earnings of -$0.63 per share for Q3 2026.

The consensus revenue estimate for PAVmed is $25 thousand for Q3 2026.

PAVmed Earnings Headlines

PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026
October 30 at 8:30 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/pavmed-to-hold-third-quarter-2026-business-update-conference-call-and-webcast-on-november-13-2026-302924383.html
Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026
October 29, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/lucid-diagnostics-to-hold-third-quarter-2026-business-update-conference-call-and-webcast-on-november-12-2026-302923219.html
Elon Musk about to bankrupt Amazon, Microsoft & Google?
Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracking a new Elon Musk project he calls the most epic AI initiative in history. The plan could give Musk access to 50 times more computing power than the rest of the world combined, a development Brown says is drawing attention from executives at Amazon, Microsoft, and Google. Brown compares the scale of this project to the SpaceX IPO, which minted thousands of millionaires overnight.tc pixel
November 2 at 1:00 AM  |  Brownstone Research (Ad)
PAVmed Inc. subsidiary Lucid Diagnostics raises $15.0 million in Series C preferred stock offering
October 23, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/pavmed-inc-subsidiary-lucid-diagnostics-raises-15-0-million-in-series-c-preferred-stock-offering/ar-AA2fTiYf
PAVmed Subsidiary Lucid Diagnostics Completes Preferred Financing
October 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/pavmed-subsidiary-lucid-diagnostics-completes-preferred-financing?utm_source=marketbeat.com&utm_medium=referral
Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing
October 22, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/lucid-diagnostics-begins-receiving-medicare-reimbursement-for-esoguard-and-closes-15-million-financing-302917430.html
See More PAVmed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PAVmed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PAVmed and other key companies, straight to your email.

About PAVmed

PAVmed (NASDAQ:PAVM) is a diversified medical technology company that develops and commercializes diagnostic and therapeutic products intended to address significant unmet needs in healthcare. Its portfolio has included medical devices, diagnostic technologies and digital health solutions, with a focus on products designed to improve disease detection, treatment and patient care.

One of PAVmed’s principal areas of activity has been its relationship with Lucid Diagnostics, a subsidiary focused on early detection of esophageal disease. Lucid’s EsoGuard molecular diagnostic test is designed to identify abnormal cells associated with Barrett’s esophagus, while the EsoCheck device is intended to collect esophageal cells in a noninvasive office-based procedure. PAVmed has also developed medical devices such as CarpX, a system designed to support minimally invasive carpal tunnel release procedures.

PAVmed was founded in 2014 by physician and entrepreneur Lishan Aklog, who has served as chairman and chief executive officer. The company is headquartered in New York and has focused primarily on developing healthcare technologies for the U.S. market, while seeking broader commercial opportunities as its products advance through regulatory and commercialization processes.

View PAVmed Profile
Earnings Tools